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than 15 days in medication coverage. Three statistical models
corresponding to the three measures of medication reﬁll persis-
tence were performed: Tobit model, logistic regression, and 
survival analysis. Control variables included demographic and
social economic information, health status, medication condi-
tions, health service utilization, and drug beneﬁt characteristics.
RESULTS: The study included 1549 members, 42.0% female,
mean age 55.7 years, with member cost-sharing of about $12
per 30 days supply. For every $1 increase in 30 day average cost-
sharing, total gap increased by 2.7% (transferred Tobit coefﬁ-
cient = 0.027, 95% CI = [0.011, 0.043], p = 0.001); the odds of
non-persistence (PDC < 80%) increased by 2.5% (OR = 1.025,
95% CI = [1.007, 1.042], p = 0.005); and the risk to have a gap
of more than 15 days increased by 1.7% (HR = 1.017, 95% CI
= [1.007, 1.027], p = 0.001). CONCLUSION: Prescription cost-
sharing was associated with a signiﬁcant and negative impact 
on medication reﬁll persistence after controlling for other con-
founders. It is important for health plans and self insured
employers to consider the implications of member contribution
on medication reﬁll persistence when making pharmacy beneﬁt
design decisions.
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OBJECTIVES: To evaluate the long-term health outcomes of
ACS patients taking clopidogrel and aspirin, either alone or 
in combination, within the California Medicaid population.
METHODS: A retrospective claims study was conducted for the
10-year period from 1995–2004. Patients were ≥19 years of age,
with ≥6 months of continuous eligibility prior to index date, and
≥1 month of continuous eligibility after index date. Patients hos-
pitalized with UA or NSTEMI were identiﬁed using ICD-9 codes
and divided into 3 subgroups: clopidogrel-only (CO), aspirin-
only (AO), and clopidogrel/aspirin (CA). Cox proportional-
hazard models were used to estimate hazard ratios (HR) for 
time to death, major bleeding events (MBE; ICD-9 codes
531.x1–535.x1), re-hospitalization, and revascularization with
covariate adjustment. The unadjusted time-to-event curves were
estimated using Kaplan-Meier (KM) techniques. RESULTS: The
UA/NSTEMI study population included 6448 patients. KM
curves showed no difference in time to MBE among the 3 groups.
With AO (n = 3738) serving as the baseline, HR for CA (n =
2071) was 1.05 (P = 0.65); HR for CO (n = 639) was 0.985 (P
= 0.93). The KM curves for CO and AO showed no difference
in time to death. However, HR for CA was 0.706 (P = 0.0030),
indicating that patients taking both drugs had a roughly 30%
lower risk of death compared with patients taking AO. In con-
trast, CA had a 50% higher risk of re-hospitalization (HR =
1.50, P < 0.0001) and revascularization (HR = 1.51, P < 0.0001)
than AO. No statistically signiﬁcant differences in risk were
found between CO and AO for re-hospitalization (HR = 0.80, P
= 0.18) or revascularization (HR = 1.18, P = 0.18). CONCLU-
SION: The results suggest patients taking clopidogrel or aspirin,
either alone or in combination, have similar long-term bleeding
risk. The combination of clopidogrel and aspirin may reduce the
risk of death compared with either drug alone. However, com-
bination therapy did not lead to a decrease in re-hospitalization
or revascularization compared with either drug alone.
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OBJECTIVES: On July 12, 2005 the Arkansas Medicaid
program implemented a prior approval policy for calcium
channel blockers (CCBs) in which Diltiazem ER, Dynacirc CR,
Nifedipine ER, XL, CC, CR, Norvasc, and Verapamil SR, SA,
were the preferred drugs. The objective of this study was to 
estimate the impact of this policy on CCB expenditures.
METHODS: This study utilized a time series panel design to
evaluate the impact of the policy using Arkansas Medicaid
administrative claims data obtained from January 2003 through
May 2006. Auto-Regressive Integrated Moving Average
(ARIMA) time series models were speciﬁed using monthly pre-
scription expenditures and utilization in the pre-policy period
(January 2003–June 2005) to forecast expenditures and utiliza-
tion in the post-policy period. The Medicaid payer perspective
was used and all prescription costs were calculated based on the
amount paid for each claim adjusted for product speciﬁc CMS
rebates. RESULTS: The average forecast expenditures for 
CCBs for August 2005–May 2006 was $426,706 (95%CI:
410,356–443,055) per month and observed expenditures were
$331,547 indicating that the policy change was associated with
a 22% reduction in CCB expenditures or $95,159 (95%CI:
78,809–111,508) per month. The average monthly savings were
$114,521 prior to January 2006 and were $75,796 after
Medicare dual eligibles began receiving Part-D beneﬁts. Non-sig-
niﬁcant reductions in CCB utilization were observed in the initial
4 months following the policy, however by May 2006, 4065
(95%CI: 3811–4319) recipients were expected to be taking
CCBs but only 3046 actually had a CCB prescription ﬁlled.
CONCLUSION: This CCB preferred drug list resulted in sub-
stantial savings of approximately $100,000 per month. Some of
the savings appear to be a result of reduced utilization of CCBs
which may indicate that other cardiovascular drugs may have
been used in place of CCBs or CCB discontinuation.
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OBJECTIVES: The Medicare Modernization Act explicitly ruled
out the possibility that the federal government could directly
negotiate drug prices as an effective way to contain costs for Part
D. Recent changes in the leadership of congress have led to a
reemergence of debate on this issue. Taking a societal perspec-
tive, we sought to quantify how much money for prescription
drugs could be saved among the elderly if prices nationwide were
equivalent to 2006 Federal Supply Schedule (FSS) prices for
several of the top selling prescription drug classes. METHODS:
Cross-sectional analysis of the nationally representative Medical
Expenditure Panel Survey, 2004. Adults > 64 years who ﬁlled a
prescription for any drug within the following classes were
included: Angiotensin Receptor Blockers, ACE inhibitors, HMG-
CoA Reductase Inhibitors (Statins), Proton Pump Inhibitors,
Non-Steroidal Anti-inﬂammatory, Histamine-2 Receptor Antag-
onists, Dihydropyridine Calcium Channel Blockers, and Steroid
Inhalers (n = 2198 individuals). The average price/pill for each
A4 Abstracts
drug-dose combination was calculated in 2006 dollars and was
compared to prices available through the November 2006 FSS.
A savings/pill was calculated to develop a nationally representa-
tive estimate of the societal savings that could be achieved if med-
ications could be obtained for FSS prices instead of current
pricing systems. RESULTS: Substitution of the FSS price could
result in a median annual per person savings in drug expendi-
tures of $308 (interquartile range, $124 to $637) for the
Medicare population, age 65 and above. The potential national
savings among these 8 classes over one year is $10.7 billion (95%
CI $10.0 billion to $11.4 billion). Among Statin medications
alone, the annual savings could be $5.9 billion (95% CI $5.4
billion to $6.4 billion) in this age group. CONCLUSION: Sub-
stantial savings in drug expenditures, in the tens of billions of
dollars, would result if Federal Supply Schedule prices were used
by Medicare in place of these commercially available prices.
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OBJECTIVES: The objective of this study was to estimate per
patient per month (PPPM) costs of medications in the six
Medicare Part D protected classes based on ﬁndings among
Medicare and dual eligible beneﬁciaries with drug coverage prior
to enactment of the beneﬁt. METHODS: Data were from the
Thomson Medstat Marketscan Medicare and Medicaid claims
databases. The study sample was constructed by identifying
patients who were enrolled either in Medicare or dually in
Medicare and Medicaid in 2004. Costs were aggregated within
each class, including patient-paid and plan-paid amounts. These
costs provided the numerators for the PPPM calculations.
Denominators were deﬁned as the aggregated patient months for
only those individuals who ﬁlled a drug within a particular class.
Drugs covered under Part B were excluded. RESULTS: The
classes where generic formulations were available (antidepres-
sants and anticonvulsants) showed lower PPPM costs ($45.31
and $50.97, respectively). The costliest class was the antiretro-
virals ($1028.13) for dual eligible patients including those age
64 and under. Among the dual eligibles over 65, immunosup-
pressants were the costliest ($657.72). In the Medicare group,
the cost of immunosuppressants ($814.86) was substantially
higher than the other ﬁve classes. The PPPM cost over all 6
classes for Medicare was $54.75, for dual eligibles it was
$157.99, and $116.35 for all patients. CONCLUSION: PPPM
costs were not uniformly high among the protected classes. The
claims data in this study allowed a “real world” check of how
much the protected classes may impact the ﬁnances of Part D.
There are differences within the classes between the dual eligible
and Medicare patients, and also within the dual eligibles by age.
This is an important message to policy makers that a change to
the structure of the protected classes in Part D may have differ-
ential effects across and also within classes.
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OBJECTIVES: Few assessments of the Medicare Part D Pre-
scription Drug Beneﬁt have been performed. We examined the
impact of the drug beneﬁt on drug utilization and out-of-pocket
expenditures. METHODS: We used pharmacy claims data from
a large national pharmacy to compare drug utilization and out-
of-pocket expenditures of Medicare eligible seniors in 2005 to
their outcomes in 2006. We used pharmacy customers aged
60–64 during the same period as a control group to capture non-
Medicare related trends in drug utilization and costs occurring
during the study period. The sample represented approximately
5.1 million unique Medicare beneﬁciaries aged 65–90 and 1.8
million unique subjects in the control group who ﬁlled and
obtained at least one prescription in pre-beneﬁt 2005 period.
RESULTS: After adjusting for individual characteristics and
socio-economic characteristics of subjects’ zip code of residence,
preliminary analyses suggest subjects’ annual drug utilization
increased by 5.5% (95% conﬁdence interval [CI] 4.7%–6.2%)
and subjects’ annual out-of-pocket expenditures decreased by
10.6% (CI 9.6%–11.9%) in 2006 as compared to 2005, net of
non-Part D related effects. Dual eligible subjects had little to no
increase in drug utilization. However, they had similar declines
in out-of-pocket expenditures as the broader beneﬁciary popu-
lation. Sensitivity analyses demonstrated that the measured
impact was not due to trend differences among different 
age groups over the study period. CONCLUSIONS: Modest
increases in prescription drug utilization and decreases in out-of-
pocket expenditures occurred for these Medicare seniors fol-
lowing the implementation of the Medicare Part D Prescription
Beneﬁt. Further work is needed to examine these patterns among
other beneﬁciaries and to evaluate the impact of these changes
on health outcomes.
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OBJECTIVES: To measure costs from complying with Medicaid
preferred drug lists (PDLs) for primary care physicians and 
cardiologists. To quantify the potential costs of a hypothetical
universal PDL for Medicare Part D as of January 2006.
METHODS: During December 2005 and January 2006 we sur-
veyed cardiologists and primary care physicians in 9 states about
their experiences with Medicaid PDLs that covered outpatient
prescriptions for statins and antihypertensives. We calculated the
opportunity cost of time spent by physicians and their staff on
requesting prior authorizations (PAs), appealing rejected PAs,
discussing PDLs with others, tracking changes to PDLs, and
receiving PDL-related training, as well as physicians’ altruistic
costs from suboptimal prescribing decisions. We used compre-
hensive prescription data from Wolters Kluwer Health (WKH)
to generate each physician’s annual prescription volume for
statins and antihypertensives separately by PDL coverage status.
We combined the survey data on PDL-related costs per physi-
cian with the WKH prescription volume data using a bootstrap
simulation to calculate total costs and the average cost per physi-
cian. We calculated the potential costs of a hypothetical univer-
sal Medicare Part D PDL by approximating the number of new
Part D prescriptions affected by PDLs and multiplying by the
survey-based average variable cost per prescription. RESULTS:
There were 986 survey respondents and 47,843 physicians with
WKH data. For statins and hypertensives, PDL cost per pre-
scription averaged $8.02 (95% CI: $7.25–$8.78)—$14.41 (95%
CI: $13.29–$15.53) off-PDL and $6.59 (95% CI: $5.91–$7.28)
on-PDL—leading to average Medicaid PDL costs per physician
of $1110 (95% CI: $1061–$1161) annually. Similar restrictions
for Medicare Part D across all therapeutic classes could have cost
